Cocrystal Pharma Inc (COCP)

$0.96 -0.02 (-1.96%)
Market Cap 13.51M
Revenue (ttm) 0.00
Net Income (ttm) -17.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 45,300
Avg Vol 79,192
Day's Range N/A - N/A
Shares Out 13.78M
Stochastic %K 8%
Beta 1.13
Analysts Strong Sell
Price Target $8.00

Company Profile

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a cl...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 262 7123
Address:
19805 North Creek Parkway, Bothell, United States
bulmar
bulmar Feb. 3 at 7:05 PM
$COCP 🗑️
0 · Reply
resurrect_momo21
resurrect_momo21 Feb. 2 at 8:52 PM
$COCP $50 before June fire works coming 🔥 bashers gonna freak the F
0 · Reply
Resurrected_Magic
Resurrected_Magic Feb. 2 at 5:51 PM
$COCP
1 · Reply
Kooguy80
Kooguy80 Jan. 31 at 1:03 AM
$COCP Next week 🏃‍♂️! 📈
1 · Reply
topstockalerts
topstockalerts Jan. 31 at 12:32 AM
After Hours Top Gainers PT2 $STAK $EJH $WETH.X $CGTL $COCP
0 · Reply
bulmar
bulmar Jan. 30 at 10:31 PM
$COCP What’s the plan Martin?
0 · Reply
bulmar
bulmar Jan. 26 at 11:10 PM
$COCP This stock is literally Momo’s abortion. Price target 50…
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 26 at 3:31 PM
$COCP RSI: 44.12, MACD: 0.0087 Vol: 0.06, MA20: 1.06, MA50: 1.03 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 · Reply
resurrect_momo21
resurrect_momo21 Jan. 23 at 7:36 PM
$COCP you don't wanna be this sad old loser in a geriatric facility since 2013 = 7207 ideas = zero winners = no money just a basher who needs a redo on life 🤣
0 · Reply
bulmar
bulmar Jan. 23 at 6:28 PM
$COCP 50 by June what a dumb ass. He bought this at 10. Read the NVDA millionaire post and make your decision.
0 · Reply
Latest News on COCP
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Dec 18, 2025, 8:00 AM EST - 6 weeks ago

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference

Dec 1, 2025, 8:00 AM EST - 2 months ago

Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Nov 14, 2025, 8:00 AM EST - 2 months ago

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 30, 2025, 8:00 AM EDT - 3 months ago

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

Oct 27, 2025, 8:00 AM EDT - 3 months ago

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

Oct 2, 2025, 8:00 AM EDT - 4 months ago

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 15, 2025, 4:30 PM EDT - 5 months ago

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 12, 2025, 9:43 AM EDT - 5 months ago

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

Sep 12, 2025, 8:00 AM EDT - 5 months ago

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

Sep 8, 2025, 8:00 AM EDT - 5 months ago

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 5 months ago

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Aug 14, 2025, 8:00 AM EDT - 6 months ago

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

Aug 5, 2025, 8:00 AM EDT - 6 months ago

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

Jul 10, 2025, 8:00 AM EDT - 7 months ago

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference

Jun 5, 2025, 8:00 AM EDT - 8 months ago

Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

May 29, 2025, 8:00 AM EDT - 8 months ago

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference

May 28, 2025, 8:00 AM EDT - 8 months ago

Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 15, 2025, 8:00 AM EDT - 9 months ago

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Apr 24, 2025, 8:00 AM EDT - 10 months ago

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

Apr 16, 2025, 8:00 AM EDT - 10 months ago

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 31, 2025, 8:00 AM EDT - 11 months ago

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Mar 6, 2025, 8:00 AM EST - 11 months ago

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide

Dec 31, 2024, 2:21 PM EST - 1 year ago

Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Dec 31, 2024, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Aug 19, 2024, 4:05 PM EDT - 1 year ago

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

Aug 15, 2024, 3:00 PM EDT - 1 year ago

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 13, 2024, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

May 1, 2024, 8:00 AM EDT - 1 year ago

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Mar 5, 2024, 8:30 AM EST - 2 years ago

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Dec 6, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Nov 29, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Nov 27, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Nov 9, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Apr 10, 2023, 8:30 AM EDT - 3 years ago

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Cocrystal Pharma Announces Participation in Virtual Investor Events

Jan 26, 2023, 8:00 AM EST - 3 years ago

Cocrystal Pharma Announces Participation in Virtual Investor Events

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Jan 23, 2023, 9:00 AM EST - 3 years ago

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

Dec 1, 2022, 4:05 PM EST - 3 years ago

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Nov 17, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

Nov 1, 2022, 4:05 PM EDT - 3 years ago

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344

Oct 26, 2022, 8:00 AM EDT - 3 years ago

Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344

Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference

Oct 5, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Oct 3, 2022, 4:05 PM EDT - 3 years ago

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Aug 8, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast

Aug 3, 2022, 9:00 AM EDT - 3 years ago

Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast

Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference

May 18, 2022, 8:00 AM EDT - 4 years ago

Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference

bulmar
bulmar Feb. 3 at 7:05 PM
$COCP 🗑️
0 · Reply
resurrect_momo21
resurrect_momo21 Feb. 2 at 8:52 PM
$COCP $50 before June fire works coming 🔥 bashers gonna freak the F
0 · Reply
Resurrected_Magic
Resurrected_Magic Feb. 2 at 5:51 PM
$COCP
1 · Reply
Kooguy80
Kooguy80 Jan. 31 at 1:03 AM
$COCP Next week 🏃‍♂️! 📈
1 · Reply
topstockalerts
topstockalerts Jan. 31 at 12:32 AM
After Hours Top Gainers PT2 $STAK $EJH $WETH.X $CGTL $COCP
0 · Reply
bulmar
bulmar Jan. 30 at 10:31 PM
$COCP What’s the plan Martin?
0 · Reply
bulmar
bulmar Jan. 26 at 11:10 PM
$COCP This stock is literally Momo’s abortion. Price target 50…
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 26 at 3:31 PM
$COCP RSI: 44.12, MACD: 0.0087 Vol: 0.06, MA20: 1.06, MA50: 1.03 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 · Reply
resurrect_momo21
resurrect_momo21 Jan. 23 at 7:36 PM
$COCP you don't wanna be this sad old loser in a geriatric facility since 2013 = 7207 ideas = zero winners = no money just a basher who needs a redo on life 🤣
0 · Reply
bulmar
bulmar Jan. 23 at 6:28 PM
$COCP 50 by June what a dumb ass. He bought this at 10. Read the NVDA millionaire post and make your decision.
0 · Reply
bulmar
bulmar Jan. 23 at 6:11 PM
$COCP 🤦
0 · Reply
Funk49R
Funk49R Jan. 22 at 5:49 AM
$COCP Is this still a phil frost co ?
1 · Reply
elon_musk22
elon_musk22 Jan. 21 at 3:19 PM
$COCP $25 is def coming fast big news gonna hit and $50 maybe and jai wei is def a psycho stalker with no stock LMFAO
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 21 at 2:17 PM
$COCP Really good write-up that perfectly summarizes COCP's present situation. So if you want to bring your COCP knowledge up to date or just discover COCP, this is required reading. https://everyticker.com/quote/COCP/analysis/cocrystal-pharma-s-antiviral-pipeline-faces-funding-cliff-a-binary-bet-on-survival-and-science-nasdaq-cocp
1 · Reply
resurrect_momo21
resurrect_momo21 Jan. 21 at 1:53 PM
$COCP bully "jai wei" ST since december 2013 15 long year losing all his mamas money bashing stocks continues to be fixated on cocrystal but knows nothing about can you imagine how much this loser hates his life what a real psycho everybody knows itLOL
0 · Reply
bulmar
bulmar Jan. 20 at 8:59 PM
$COCP I know, the market was down. Check the chart this thing is down big time !!
0 · Reply
bulmar
bulmar Jan. 20 at 3:43 PM
$COCP Good Morning! Yeah this about right!
0 · Reply
resurrect_momo21
resurrect_momo21 Jan. 16 at 4:11 PM
$COCP $50 well before June $VERO peeps start adding cocrystal pharma fast
0 · Reply
bulmar
bulmar Jan. 15 at 5:24 PM
$COCP 🥱💩
0 · Reply
LUCKY_Cool_Cat
LUCKY_Cool_Cat Jan. 14 at 3:26 PM
$COCP https://www.nature.com/articles/s41560-025-01904-8
1 · Reply
LUCKY_Cool_Cat
LUCKY_Cool_Cat Jan. 11 at 4:43 PM
$COCP https://www.tipranks.com/news/the-fly/cocrystal-pharma-receives-nih-sbir-award-to-advance-influenza-inhibitor-program-thefly
1 · Reply
smartmoney43
smartmoney43 Jan. 10 at 12:44 AM
$COCP looks interesting
1 · Reply